Literature DB >> 23381000

Prostate cancer: The androgen receptor remains front and centre.

Philip J Saylor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23381000     DOI： 10.1038/nrclinonc.2013.14

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.

Authors:  Matthew R Smith
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

4.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Authors:  Medha S Darshan; Matthew S Loftus; Maria Thadani-Mulero; Benjamin P Levy; Daniel Escuin; Xi Kathy Zhou; Ada Gjyrezi; Chantal Chanel-Vos; Ruoqian Shen; Scott T Tagawa; Neil H Bander; David M Nanus; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2011-07-28       Impact factor: 12.701

5.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Authors:  Meng-Lei Zhu; Craig M Horbinski; Mark Garzotto; David Z Qian; Tomasz M Beer; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

6.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

Review 7.  Metabolic complications of androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

8.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  9 in total
  14 in total

1.  Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.

Authors:  Jia-Xuan Qiu; Zhi-Wei Zhou; Zhi-Xu He; Ruan Jin Zhao; Xueji Zhang; Lun Yang; Shu-Feng Zhou; Zong-Fu Mao
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

2.  Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.

Authors:  Päivi Sutinen; Vesa Rahkama; Miia Rytinki; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2014-08-15

3.  Chrebp regulates the transcriptional activity of androgen receptor in prostate cancer.

Authors:  Xue-Lei Wang; Xiao-Fei Wen; Rong-Bing Li; Bin Liu; Guang-Ming Qiu; Ji-Ling Wen; Yue-Min Wang
Journal:  Tumour Biol       Date:  2014-05-21

4.  Adiponectin inhibits VEGF-A in prostate cancer cells.

Authors:  Qiruo Gao; Junhua Zheng; Xudong Yao; Bo Peng
Journal:  Tumour Biol       Date:  2015-01-15

Review 5.  Mini-review: androgen receptor phosphorylation in prostate cancer.

Authors:  Garrett Daniels; Zhiheng Pei; Susan K Logan; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

6.  Pituitary tumor-transforming gene 1 regulates invasion of prostate cancer cells through MMP13.

Authors:  Yun-Hua Lin; Yong Tian; Jun-Sheng Wang; Yong-Guang Jiang; Yong Luo; Ya-Tong Chen
Journal:  Tumour Biol       Date:  2015-07-23

Review 7.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

8.  VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin.

Authors:  Feng Liu; Jihong Wang; Qiang Fu; Xinru Zhang; Ying Wang; Jialin Liu; Jianwen Huang; Xiangguo Lv
Journal:  Tumour Biol       Date:  2015-11-13

9.  Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.

Authors:  Katerina Mardilovich; Mads Gabrielsen; Lynn McGarry; Clare Orange; Rachana Patel; Emma Shanks; Joanne Edwards; Michael F Olson
Journal:  Mol Cancer Ther       Date:  2014-10-24       Impact factor: 6.261

10.  Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells.

Authors:  Zhi-Wei Zhou; Xing-Xiao Li; Zhi-Xu He; Shu-Ting Pan; Yinxue Yang; Xueji Zhang; Kevin Chow; Tianxin Yang; Jia-Xuan Qiu; Qingyu Zhou; Jun Tan; Dong Wang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-12       Impact factor: 4.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.